News - Merck & Co


Current filters:

Merck & Co

Popular Filters

226 to 250 of 279 results

Merck & Co out to lead in hepatitis C


US drugs giant Merck & Co (NYSE: MRK) aims to become a leader in the hepatitis C space, the company’s…

Anti-viralsMerck & CoMergers & AcquisitionsPharmaceuticalResearch

Merck & Co selects Idera vaccine candidates


Idera Pharmaceuticals (Nasdaq: IDRA) says that US drugs giant that Merck & Co (NYSE: MRK) has selected…

Idera PharmaceuticalsLicensingMerck & CoPharmaceuticalResearchVaccines

Takeda ends Daxas co-promotion with MSD; Actos law suits


Japan’s largest drugmaker, Takeda Pharmaceuticals (TYO: 4502) says that it has reached a mutual…

ActosDaxasDiabetesLegalLicensingMerck & CoNycomedPharmaceuticalRespiratory and PulmonaryTakeda Pharmaceuticals

Merck gains expanded Isentress indication; lowers price of drug for ADAps


In two pieces of HIV/AIDS-related news for US drugs giant Merck & Co (NYSE: MRK), the company’s…

Anti-viralsIsentressMerck & CoNorth AmericaPharmaceuticalPricingRegulation

Merck buys in Exelixis’ PI3K-Delta program; returns product to Acumen


California-based Exelixis (Nasdaq: EXEL) says it has granted US drug giant Merck & Co (NYSE: MRK) an…

Acumen PharmaceuticalsExelixisInflammatory diseasesLicensingMerck & CoNeurologicalOncologyPharmaceutical

Pfizer tops social media presence ranking


Cegedim Strategic Data (CSD), a provider of integrated health care market research and worldwide promotional…

Markets & MarketingMerck & CoNovartisPfizerPharmaceutical

More news briefs from ASH meeting


In ongoing news from the American Society of Hematology (ASH) meeting taking place in San Diego, Swiss…

AmgenBiotechnologydaratumumabExjadeGenmabMerck & CoNovartisNplateOncologyPharmaceuticalResearchZolinza

Mochida diabetes deal with Merck; Vanda links with Megapharm


Japanese mid-sized drugmaker Mochida Pharmaceutical (TYO: 4534) saw its shares jump 5.8% to 900 yen,…

BiotechnologyDiabetesFanaptLicensingMegapharmMerck & CoMochida PharmaceuticalNeurologicalPharmaceuticalVanda Pharmaceuticals

Merck slammed over drug pricing


In another swipe at US pharma giant Merck & Co (NYSE: MRK), the AIDS Healthcare Foundation (AHF) has…

Anti-viralsIsentressMerck & CoNorth AmericaPharmaceuticalPricing

NICE wants more data on Daxas


UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today issued final…

DaxasEuropeMerck & CoPharmaceuticalPricingRegulationRespiratory and Pulmonary

Dendreon cashes in Victrelis royalty


US pharma company Dendreon (Nasdaq: DNDN) says that it has agreed to sell for $125 million in cash its…

Anti-viralsBiotechnologyDendreonFinancialLicensingMerck & CoOncologyPharmaceuticalProvengeVictrelis

Diabetes Rxing in China and S Korea


Dipeptidyl peptidase IV (DPP-IV) inhibitors are prescribed more commonly for the treatment of type 2…

Asia-PacificDiabetesGalvusJanuviaMarkets & MarketingMerck & CoNovartisPharmaceuticalPricing

Merck & Co commits $1.5 billion to R&D in China over next five years


Adding to the flow of pharmaceutical investment into the BRIC (Brazil, Russia, India and China) countries,…

Asia-PacificFinancialMerck & CoPharmaceuticalResearch

Merck & Co to pay $950 million for illegal marketing of Vioxx


US pharma giant Merck & Co (NYSE: MRK) has agreed to pay $950 million to resolve criminal charges and…

FinancialLegalMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalVioxx

Hepatitis C drug market in Mexico expected to double to $104 million in 2015


The hepatitis C virus (HCV) market in Mexico will nearly double from $56 million in 2010 to $104 million…

Anti-viralsIncivekMarkets & MarketingMerck & CoPharmaceuticalRocheSouth AmericaVertexVictrelis

FDA panel gives unanimous backing for Merck & Co’s Vytorin for some kidney disease patients


US drug giant Merck & Co (NYSE: MRK) said yesterday that the Endocrinologic and Metabolic Drugs Advisory…

Cardio-vascularMerck & CoNorth AmericaPharmaceuticalRegulationVytorin

Hepatitis B vaccines market forecast to show moderate growth until 2018


The global hepatitis B vaccines market is estimated to be worth $997.0 million in 2010, and is forecast…

Anti-viralsGlaxoSmithKlineMarkets & MarketingMerck & CoPharmaceuticalVaccines

226 to 250 of 279 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top